9f6a2480-748d-414b-be0b-36be34c24037
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 60.1697467488022
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.550
- OXIDATIVE_PHOSPHORYLATION+0.510
- MYC_TARGETS_V1+0.490
- G2M_CHECKPOINT+0.480
- MYC_TARGETS_V2+0.460
- PEROXISOME+0.380
- FATTY_ACID_METABOLISM+0.350
- CHOLESTEROL_HOMEOSTASIS+0.330
- MTORC1_SIGNALING+0.330
- PROTEIN_SECRETION+0.290
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.520
- ALLOGRAFT_REJECTION-0.460
- IL6_JAK_STAT3_SIGNALING-0.440
- INFLAMMATORY_RESPONSE-0.440
- COAGULATION-0.380
- TNFA_SIGNALING_VIA_NFKB-0.380
- ANGIOGENESIS-0.350
- COMPLEMENT-0.330
- IL2_STAT5_SIGNALING-0.310
- KRAS_SIGNALING_UP-0.310
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR10900021 | — | — | 0.903 |
| 2 | f354d13d-89ec-4ed6-821d-df3ab230fc91 | — | — | 0.899 |
| 3 | TCGA-46-3768-01A-01R-0980-07 | — | cohortSQ2 | 0.897 |
| 4 | C3N-03882 | — | cohortSQ2 | 0.895 |
| 5 | SRR35579804 | — | C | 0.890 |
| 6 | TCGA-22-5491-01A-01R-1635-07 | — | cohortSQ2 | 0.889 |
| 7 | TCGA-DK-AA71-01A-31R-A39I-07 | — | — | 0.889 |
| 8 | SRR2932839 | — | — | 0.889 |
| 9 | TCGA-A8-A06Z-01A-11R-A00Z-07 | — | B | 0.887 |
| 10 | TCGA-A8-A06O-01A-11R-A00Z-07 | — | B | 0.884 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.550 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.510 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.490 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.480 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.460 | Idelalisib | — uncovered |
| PEROXISOME | 0.380 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.350 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.330 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.330 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.290 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.290 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.280 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.230 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.220 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.220 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.210 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.200 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.180 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.160 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.150 | Cobimetinib | — uncovered |